The payment codes, effective Feb. 11, are for bebtelovimab. The drug was authorized last week by the FDA to treat patients who are at high risk for progression to severe COVID-19 or hospitalization.
There are several new codes:
- Q0222: injection, bebtelovimab, 175 mg
- M0222: intravenous injection, bebtelovimab, including injection and post-administration monitoring
- M0223: intravenous injection, bebtelovimab, including injection and post-administration monitoring in the home or residence
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.